Galmed Pharmaceuticals Ltd. diskutieren
Galmed Pharmaceuticals Ltd.
WKN: A1XFUX / Symbol: GMED / Name: Galmed Pharma / Aktie / Biotechnologie & medizinische Forschung / Small Cap /
0,26 €
-3,85 %
Globus Medical, Inc. (NYSE: GMED) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
Ratings data for GMED provided by MarketBeat
Globus Medical, Inc. (NYSE: GMED) is now covered by analysts at Roth Mkm. They set a "buy" rating and a $75.00 price target on the stock.
Ratings data for GMED provided by MarketBeat
Globus Medical, Inc. (NYSE: GMED) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $70.00 price target on the stock.
Ratings data for GMED provided by MarketBeat
Globus Medical, Inc. (NYSE: GMED) had its price target raised by analysts at Stifel Nicolaus from $61.00 to $64.00. They now have a "buy" rating on the stock.
Ratings data for GMED provided by MarketBeat
Globus Medical, Inc. (NYSE: GMED) was upgraded by analysts at BTIG Research from a "neutral" rating to a "buy" rating. They now have a $60.00 price target on the stock.
Ratings data for GMED provided by MarketBeat
Globus Medical, Inc. (NYSE: GMED) had its price target raised by analysts at Stifel Nicolaus from $64.00 to $70.00. They now have a "buy" rating on the stock.
Ratings data for GMED provided by MarketBeat
Globus Medical, Inc. (NYSE: GMED) had its price target raised by analysts at BTIG Research from $60.00 to $63.00. They now have a "buy" rating on the stock.
Ratings data for GMED provided by MarketBeat
Globus Medical, Inc. (NYSE: GMED) had its price target raised by analysts at Barclays PLC from $83.00 to $85.00. They now have an "overweight" rating on the stock.
Ratings data for GMED provided by MarketBeat
Globus Medical, Inc. (NYSE: GMED) was upgraded by analysts at Piper Sandler from a "neutral" rating to an "overweight" rating. They now have a $80.00 price target on the stock, up previously from $60.00.
Ratings data for GMED provided by MarketBeat
Globus Medical, Inc. (NYSE: GMED) had its price target raised by analysts at BTIG Research from $63.00 to $72.00. They now have a "buy" rating on the stock.
Ratings data for GMED provided by MarketBeat
Globus Medical, Inc. (NYSE: GMED) had its price target raised by analysts at BTIG Research from $72.00 to $75.00. They now have a "buy" rating on the stock.
Ratings data for GMED provided by MarketBeat
Globus Medical, Inc. (NYSE: GMED) had its price target raised by analysts at Royal Bank of Canada from $76.00 to $78.00. They now have an "outperform" rating on the stock.
Ratings data for GMED provided by MarketBeat
Globus Medical, Inc. (NYSE: GMED) had its price target raised by analysts at Barclays PLC from $85.00 to $93.00. They now have an "overweight" rating on the stock.
Ratings data for GMED provided by MarketBeat
Neueste Beiträge
Royal_Bank_of_Canada in Intra-Cellular Therapies Inc. diskutieren